Plasma Oxytocin Response to Oral Estrogens in Healthy Controls and AVP-Deficiency

Exclusion Criteria

• •Part 1
• •1. Participation in a trial with investigational drugs within 30 days
• •2. BMI \>30
• •3. Age \>50
• •4. Illicit substance use (except for cannabis) during the last 30 days
• •5. Consumption of alcoholic beverages \>15 drinks/week
• •6. Tobacco smoking \>10 cigarettes/day
• •7. Pregnancy and breastfeeding
• •8. Hormonal contraception
• •9. Migraine with and without aura
• •10. Any cardiometabolic, cardiovascular, and hematological diseases (including deep vein thrombosis/pulmonary embolism and thrombophilia (DVT/PE))
• •11. Active liver dysfunction or alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) levels 2.5 times above the normal range
• •12. Diagnosed chronic kidney disease (CKD) \> grade III (GRF \< 30ml/min)
• •Part 2
• •1. Participation in a trial with investigational drugs within 30 days
• •2. BMI \>30
• •3. Age \>50
• •4. Illicit substance use (except for cannabis) during the last 30 days
• •5. Consumption of alcoholic beverages \>15 drinks/week
• •6. Tobacco smoking \>10 cigarettes/day
• •7. Pregnancy and breastfeeding
• •8. Hormonal contraception
• •9. Migraine with and without aura
• •10. Any cardiometabolic, cardiovascular, and hematological diseases (including DVT/PE and Thrombophilia)
• •11. Active liver dysfunction or alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) levels 2.5 times above the normal range
• •12. Diagnosed CKD \> grade III (GRF \< 30ml/min)